Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Khaleel Ashraf (NPI 1760437925)

Field	Value
Entity Type	Individual
Organization	Khaleel Ashraf
Address	513 Brookwood Blvd Ste 275
City	Birmingham
State	AL
ZIP	35209
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 24, 2006

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

Revenue concentration is extremely high: the precomputed top 3 Medicare codes account for 81.9% of this provider's total Medicare revenue, driven by J9271 ($434.6K, 32.1% of Medicare revenue), J1568 ($399.6K, 29.5%), and J1569 ($274.3K, 20.3%). These three codes together dominate the $1.4M in Medicare revenue reported for this provider, indicating that a small set of high-cost infusible products are the primary revenue drivers.

The code mix points to an infusion-focused hematology/oncology practice that provides both oncology immunotherapy and high-volume immune globulin treatments: J9271 is pembrolizumab (an oncology immunotherapy) with 10.6K claims, while J1568 (12.1K claims) and J1569 (7.6K claims) are immune globulin products used for IVIG infusions. Presence of chemotherapy/infusion codes such as 96413, 96365 and add-on infusion codes confirms on-site administration capability and routine delivery of infusible specialty drugs.

This provider is effectively single-payer in the dataset: total Medicare revenue is $1.4M and there is no Medicaid billing on file, so Medicaid contributes $none to reported revenue. That concentration in Medicare makes the provider highly exposed to Medicare reimbursement policy and utilization changes, and it suggests limited engagement with Medicaid patient populations or contracts.

Competitive standing varies by product: for the high-revenue IVIG product J1568 the provider ranks #22 of 381 nationally (94th percentile) which places them among the higher-volume national reporters for that product, while J1569 ranks #88 of 542 (84th percentile) indicating a strong but not leading position. By contrast, pembrolizumab (J9271) is at #1102 of 1841 (39th percentile), a more modest national position for that oncology drug despite its being the single largest revenue line item. Note that these rank descriptors are characterized in the source as typical or unremarkable for many codes even at high percentiles.

Operational intensity is supported by high-volume administration and support codes: infusion-related administration codes such as 96366 show 611 claims and are labeled "notably above typical national volume" (rank #122 of 2976, 96th percentile), while 96375 (764 claims, 95th percentile) and 96365 (362 claims, 92nd percentile) are also elevated. High volumes of lab/venipuncture codes (85025 with 1.1K claims at the 94th percentile and 36415 with 873 claims at the 96th percentile) further indicate on-site phlebotomy and laboratory work consistent with an infusion clinic workflow.

Face-to-face evaluation and management visits generate only a small share of Medicare revenue relative to drug/infusion lines: 99214 appears with 593 claims and $50.4K (3.7% of Medicare revenue) and 99215 has 107 claims and $12.9K (1.0%), showing that E/M services are a secondary revenue component compared with infusible drug administration. This mix suggests referrals and visit activity are driven primarily by infusion episodes rather than high-volume office-based management visits.

Provider tenure is long: the NPI was enumerated on 2006-05-24 (~20 years ago), which indicates an established presence in the market and potential continuity of referral relationships needed to sustain high-volume IV infusion services. Longevity combined with concentrated drug revenue suggests a stable operational model focused on specialty infusions.

Concentration risk is notable from a strategic perspective because a few high-cost drugs dominate receipts: the practice’s financial performance depends heavily on continued utilization and reimbursement for pembrolizumab and the two IVIG products (J9271, J1568, J1569). Any shifts in payer coverage, drug supply, or referral patterns for these specific agents could materially affect this provider’s Medicare revenue given the heavy dependence on those lines.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

32 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,600	$40	$434.6K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	12,110	$30	$399.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	7,620	$40	$274.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	590	$90	$50.4K
J1437	Injection, ferric derisomaltose, 10 mg	2,400	$20	$38.4K
J0897	Injection, denosumab, 1 mg	1,800	$20	$32.4K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	3,660	$10	$22K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	360	$50	$16.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	150	$90	$13.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	110	$120	$12.9K

Showing 1–10 of 32

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 32 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Khaleel Ashraf — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

32 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	25	30	19,900	$40	$827.2K
J1568	8	30	5,180	$30	$316.2K
J1569	2	10	5,120	$40	$179.3K
J0897	140	200	3,120	$20	$97.7K
J1437	26	40	3,000	$20	$59.1K
J0885	2	10	3,660	$10	$32.3K
96413	78	150	150	$90	$20.2K
99214	597	7,330	120	$80	$16.8K
99233	1,390	1,860	80	$90	$13.4K
99232	1,908	2,530	100	$60	$13.3K

Showing 1–10 of 32

Related Providers

Other providers that share a Tax Identification Number (TIN) with Khaleel Ashraf, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sylacauga Health Care Authority Inc	AL	Rural Acute Care Hospital	$0	$4.2M
Elquis Castillo	AL	Medical Oncology Physician	$2.5M	$0
Allen Yeilding	AL	Hematology & Oncology Physician	$980.4K	$0
Michael Gibson	AL	Interventional Pain Medicine Physician	$359.2K	$0
Song Yu	AL	Family Medicine Physician	$314.9K	$590
David Mooney	AL	Hematology & Oncology Physician	$303.4K	$0
Nitin Chhabra	GA	Pain Medicine (Anesthesiology) Physician	$276.7K	$0
Alejandro Garcia	AL	Hematology & Oncology Physician	$230.4K	$0
Shawnta Anakwah	AL	Hematology & Oncology Physician	$213K	$0
Jonathan Bridges	AL	Hematology & Oncology Physician	$204.6K	$0

Nearby Providers

Other providers in the same ZIP code as Khaleel Ashraf, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Core Diagnostic Laboratories LLC	AL	Clinical Medical Laboratory	$1.3M	$44.2M
Lab Works, LLC	AL	Clinical Medical Laboratory	$738.4K	$41.6M
Valentines Home Care, Inc.	AL	Durable Medical Equipment & Medical Supplies	$0	$13.6M
Devansh Lab Werks,inc	AL	Clinical Medical Laboratory	$1.9M	$5.9M
Grayson And Associates PC	AL	Psychiatry Physician	$0	$5M
Affinity Acquisitions, LLC	AL	Community Based Hospice Care Agency	$0	$4.8M
Metro Pediatrics PC	AL	Specialist	$0	$4.5M
Birmingham Radiological Group PC	AL	Diagnostic Radiology Physician	$0	$3.5M
Proteus Molecular And Clinical Lab LLC	AL	Clinical Medical Laboratory	$236.9K	$3.2M
Greg Eudy	AL	Rheumatology Physician	$3.3M	$0

Khaleel Ashraf — Billing Profile & Reimbursement Data

Sign up for Khaleel Ashraf — Billing Profile & Reimbursement Data policy alerts

Khaleel Ashraf — Billing Profile & Reimbursement Data

Sign up for Khaleel Ashraf — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References